Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RZLT
stocks logo

RZLT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
--
--
-0.192
-12.73%
--
--
-0.228
-15.56%
--
--
-0.251
-3.46%
Estimates Revision
The market is revising No Change the revenue expectations for Rezolute, Inc. (RZLT) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -76.59%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-48.12%
In Past 3 Month
Stock Price
Go Down
down Image
-76.59%
In Past 3 Month
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.800
sliders
Low
12.00
Averages
16.14
High
20.00
Current: 1.800
sliders
Low
12.00
Averages
16.14
High
20.00
H.C. Wainwright
Douglas Tsao
Buy
downgrade
$14 -> $5
2025-12-12
New
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$14 -> $5
2025-12-12
New
downgrade
Buy
Reason
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Rezolute to $5 from $14 and keeps a Buy rating on the shares. The firm is "surprised and disappointed "by the negative results of the sunRIZE study, but it still sees a path forward. The analyst continues to see value in the shares and pushed out the launch of ersodetug in congenital hyperinsulinism from 2027 to 2028.
Lucid Capital
Buy
downgrade
$76 -> $66
2025-12-11
New
Reason
Lucid Capital
Price Target
$76 -> $66
2025-12-11
New
downgrade
Buy
Reason
Lucid Capital lowered the firm's price target on Xoma (XOMA) to $66 from $76 and keeps a Buy rating on the shares. The company's partner Rezolute (RZLT) announced the Phase 3 sunRIZE clinical trial evaluating ersodetug for the treatment of congenital hyperinsulinism did not achieve its primary and a key secondary endpoint, the analyst tells investors in a research note. Lucid reduced the probability of success for ersodetug to 30% from 80%.
Leerink
David Risinger
Outperform -> NULL
downgrade
$58 -> $45
2025-12-11
New
Reason
Leerink
David Risinger
Price Target
$58 -> $45
2025-12-11
New
downgrade
Outperform -> NULL
Reason
Leerink analyst David Risinger lowered the firm's price target on Xoma (XOMA) to $45 from $58 and keeps an Outperform rating on the shares. The firm removed RZ358 royal contributions from the company's model after Xoma's partner Rezolute (RZLT) announced a Phase 3 study failure. It believes RZ358's growth prospects are still "robust" despite the failure in congenital hyperinsulinism.
Wedbush
Yun Zhong
Outperform -> Neutral
downgrade
$12 -> $1
2025-12-11
New
Reason
Wedbush
Yun Zhong
Price Target
$12 -> $1
2025-12-11
New
downgrade
Outperform -> Neutral
Reason
Wedbush analyst Yun Zhong downgraded Rezolute to Neutral from Outperform with a price target of $1, down from $12.
Wedbush
Outperform
to
Neutral
downgrade
$12 -> $1
2025-12-11
New
Reason
Wedbush
Price Target
$12 -> $1
2025-12-11
New
downgrade
Outperform
to
Neutral
Reason
As previously reported, Wedbush downgraded Rezolute to Neutral from Outperform with a price target of $1, down from $12, after the negative top-line data from the Phase 3 study of ersodetug in congenital hyperinsulinism. The firm has removed both the cHI and the tumor-related hyperinsulinism programs from its valuation, despite management's unchanged confidence in the ongoing open-label Phase 3 upLIFT study in tumor HI. Rezolute plans to conduct a thorough analysis of efficacy and collect input from key opinion leaders, after which management will request a meeting with the Food and Drug Administration under the Breakthrough Therapy designation to discuss the next steps for the program.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$104 -> $97
2025-12-11
New
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$104 -> $97
2025-12-11
New
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Xoma (XOMA) to $97 from $104 and keeps a Buy rating on the shares after removing ersodetug from the firm's projections. Xoma's downside buffer from its broad set of partnered assets remains intact, even though today's share weakness reflects the loss of a potential near-term revenue driver in ersodetug, a reaction that appears excessive, the analyst tells investors in a research note. The failed Phase 3 results at partner Rezolute (RZLT) remove a 2027 launch opportunity, but the long-term depth and diversification of Xoma's portfolio still support a positive outlook, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rezolute Inc (RZLT.O) is -1.70, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Rezolute Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.99
Current PE
-1.70
Overvalued PE
-0.77
Undervalued PE
-5.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.04
Current PS
0.00
Overvalued PS
136.50
Undervalued PS
-102.42
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RZLT News & Events

Events Timeline

(ET)
2025-12-11
09:40:00
Rezolute Inc Trading Halted Due to Volatility Trading Pause
select
2025-12-11
09:10:00
Xoma Shares Drop to $27.00 After Partner Rezolute's Study Failure
select
2025-12-11
09:00:00
Rezolute Shares Down 88% to $1.27 in Pre-Market After Phase 3 Study Data
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-12Benzinga
PinnedGenetic Disease Company Sees Stock Plummet 90% After Lead Drug Trial Fails, Losing Billion-Dollar Valuation

  • Stock Performance: Rezolute Inc's stock (NASDAQ: RZLT) plummeted 88.76% to $1.23, with a trading volume of 82.25 million, significantly higher than its average of 1.597 million.

  • Phase 3 Study Results: The Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism did not meet its primary or key secondary endpoints, showing no statistically significant reduction in hypoglycemia events compared to placebo.

  • Safety Observations: While safety data were generally favorable, two participants experienced serious hypersensitivity reactions leading to early discontinuation of the drug.

  • Future Studies: The ongoing Phase 3 upLIFT study for tumor hyperinsulinism is expected to release topline results in the second half of 2026.

[object Object]
Preview
9.0
12-11NASDAQ.COM
PinnedRezolute Reports Phase 3 SunRIZE Study Does Not Achieve Primary and Secondary Goals

  • Study Results: Rezolute, Inc. announced that its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism did not meet its primary endpoint regarding hypoglycemia events, showing only a 45% reduction compared to a 40% improvement in the placebo group.

  • Secondary Endpoint Findings: The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily time in hypoglycemia at the highest dose of ersodetug, which was not statistically significant against a 5% increase in the placebo group.

  • Dosage and Administration: The study administered ersodetug at doses of 5 and 10 mg/kg every other week for three doses, followed by every four weeks, achieving target drug concentrations across all age groups.

  • Future Studies: The ongoing Phase 3 upLIFT study for tumor hyperinsulinism is expected to release topline results in the second half of 2026.

[object Object]
Preview
9.0
12-11SeekingAlpha
PinnedRezolute's Lead Asset Fails Late-Stage Trial, Causing Stock Drop

  • Ersodetug Trial Results: Rezolute's lead asset, ersodetug, failed to meet primary and secondary endpoints in a Phase 3 trial for congenital hyperinsulinism, leading to an ~89% drop in shares during premarket trading.

  • Safety Findings: Despite the trial's failure, safety findings were generally favorable, and Rezolute plans to discuss next steps with the FDA due to ersodetug's Breakthrough Therapy Designation.

  • Ongoing Studies: Rezolute is currently conducting another Phase 3 study, the upLIFT trial, for the antibody drug in tumor hyperinsulinism, with topline data expected in the second half of 2026.

  • Market Outlook: The company continues to discuss clinical progress and market opportunities for ersodetug in hyperinsulinism, despite the recent setback in trial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rezolute Inc (RZLT) stock price today?

The current price of RZLT is 1.8 USD — it has increased 28.57 % in the last trading day.

arrow icon

What is Rezolute Inc (RZLT)'s business?

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

arrow icon

What is the price predicton of RZLT Stock?

Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rezolute Inc (RZLT)'s revenue for the last quarter?

Rezolute Inc revenue for the last quarter amounts to -19.82M USD, increased 16.98 % YoY.

arrow icon

What is Rezolute Inc (RZLT)'s earnings per share (EPS) for the last quarter?

Rezolute Inc. EPS for the last quarter amounts to -17430000.00 USD, increased 8.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rezolute Inc (RZLT)'s fundamentals?

The market is revising No Change the revenue expectations for Rezolute, Inc. (RZLT) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -76.59%.
arrow icon

How many employees does Rezolute Inc (RZLT). have?

Rezolute Inc (RZLT) has 71 emplpoyees as of December 13 2025.

arrow icon

What is Rezolute Inc (RZLT) market cap?

Today RZLT has the market capitalization of 166.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free